Comparison of the effects on glycaemic control and β‐cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel‐group trial (the CONFIDENCE study)
Journal of Internal Medicine2014Vol. 277(1), pp. 137–150
Citations Over TimeTop 10% of 2014 papers
Wen Xu, Yan Bi, Zilin Sun, Jingjia Li, Lixin Guo, Tao Yang, Guifu Wu, Lihong Shi, Feng Zhang, Lei Qiu, Q. Li, Xiaohui Guo, Zuojie Luo, J. Lu, Zhongyan Shan, Wenying Yang, Qiuhe Ji, Li Yan, H. Li, Xuefeng Yu, Shujia Li, Zhiguang Zhou, Xiaoyi Lv, Zerong Liang, Shuo Lin, Longyi Zeng, Jinhua Yan, Linong Ji, Jianping Weng
Abstract
All three agents showed efficacy regarding glycaemic control and metabolic benefits; however, exenatide showed the greatest efficacy. β-cell function improved in all treatment groups; hence, early initiation of β-cell-protective therapy may halt the decline in β-cell function in type 2 diabetes.
Related Papers
- → Long-term glycaemic control with pioglitazone in patients with type 2 diabetes(2004)38 cited
- → New once‐weekly formulation of exenatide for type 2 diabetes(2010)3 cited
- → Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes receiving metformin(2009)
- → Pioglitazone Exhibits a Beneficial Effect on CIMT in Patients with Type 2 Diabetes(2006)
- Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis(2007)